Technological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
World Journal of Urology · 2025
DOI: 10.1007/s00345-024-05438-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift World Journal of Urology, 2025. Verfasst von Zhixiang Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Lasers, Solid-State. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Major Science and Technology projects of Changzhou Health Committee.
Abstract (Originalsprache)
PURPOSE: The purpose of this study was to investigate the efficacy of Transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology in the treatment of benign prostatic hyperplasia (BPH), with a focus on preserving sexual function postoperatively. METHODS: Conducted as a multicenter, prospective, single-blind randomized controlled trial, this study enrolled sexually active male patients with BPH. Participants were randomized into three groups: standard HoLEP (Group A), single-n technology (Group B), and innovative double-n technology (Group C), which emphasizes the preservation of the urethral mucosa and nearby structures. The primary endpoints included maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), and International Index of Erectile Function (IIEF). RESULTS: Of the 180 initial participants, 139 completed the study. All groups showed significant improvements in Qmax and IPSS. Initial declines in IIEF scores were noted across all groups, stabilizing to baseline by 3 months without further improvement. Group A had modest antegrade ejaculation rates, starting at 15.4% at 3 months and reaching 23.1% at 12 months. Group B showed a significant improvement, with AE rates rising from 31.8% at 3 months to 45.5% at 12 months, significantly higher than Group A (p < 0.05). Group C had the highest AE rates, starting at 57.8% at 3 months and reaching 77.8% at 12 months, significantly surpassing both Group A and B (p < 0.05). Regarding semen reduction, Group A had 100% reduction at 3 months, which decreased to 77.8% at 12 months. Group B followed a similar trend, from 100% at 3 months to 68.2% at 12 months. Group C showed a more pronounced decline, starting at 84.6% at 3 months and dropping to 37.1% at 12 months, with values significantly lower than both Groups A and B (p < 0.05). CONCLUSIONS: The double-n HoLEP technique shows promising results in improving urinary symptoms while better preserving ejaculatory function and sexual quality of life in BPH patients. This technique could offer a significant advancement in the surgical management of BPH, particularly for sexually active patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China.
- Department of Urology, Jintan Affiliated Hospital of Jiangsu University, Changzhou, China.
- Department of Urology, Second Affiliated Hospital of Wannan Medical College, Wuhu, China. syjblb@163.com.
- Department of Urology, Zhangjiagang Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China. wangrong2024@suda.edu.cn.
Förderung
- Major Science and Technology projects of Changzhou Health Committee
Zitieren
APA
Gao, Z., Wang, P., Liu, H., Ding, Y., Xu, L., Sun, Z., Du, R., Gu, L., Shen, Y., & Wang, R. (2025). Technological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. World Journal of Urology. https://doi.org/10.1007/s00345-024-05438-8
Vancouver
Gao Z, Wang P, Liu H, Ding Y, Xu L, Sun Z, et al. Technological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. World Journal of Urology. 2025. doi:10.1007/s00345-024-05438-8
BibTeX
@article{Gao2025,
author = {Gao, Zhixiang and Wang, Ping and Liu, Haiyong and Ding, Yue and Xu, Li and Sun, Zhiwei and Du, Renji and Gu, Lijuan and Shen, Yajun and Wang, Rong},
title = {Technological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia},
journal = {World Journal of Urology},
year = {2025},
doi = {10.1007/s00345-024-05438-8}
}
EUVIMED